Clario, a provider of software to help drugmakers advance treatments through clinical trials, has filed confidentially for an initial public offering and is targeting a valuation of more than $10 billion, people familiar with the matter said. The Philadelphia-based company is working with underwriters including JPMorgan Chase & Co., Morgan Stanley, Jefferies Financial Group Inc. and UBS Group AG, according to the people. It’s targeting next year for a listing, one of the people said.
Read the full article: Drug-Trial Software Maker Clario Files Confidentially for IPO //
Source: https://www.bloomberg.com/news/articles/2024-06-25/drug-trial-software-maker-clario-files-confidentially-for-ipo